Filing identity and business context
Important identity mismatch: The request identifies TALPHERA, INC., but the supplied 10-Q is for AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), filed November 6, 2019, for the quarter ended September 30, 2019. Verify the filing is the intended company before relying on this summary.
AcelRx develops and commercializes medicines for acute pain in medically supervised settings. Its U.S. commercial launch of DSUVIA began in Q1 2019; Zalviso is marketed in Europe by Grünenthal, while its U.S. NDA resubmission was still being evaluated. DZUVEO was approved in Europe, but AcelRx had not secured a European commercialization partner.
Financial results and liquidity
Amounts below are in millions of dollars unless stated otherwise.
| Metric | Q3 2019 | Q3 2018 | Nine months 2019 | Nine months 2018 |
|---|---|---|---|---|
| Total revenue | $0.608 | $0.377 | $1.814 | $1.538 |
| Net product sales | $0.116 | $0 | $0.218 | $0 |
| Operating expenses | $14.142 | $9.705 | $41.027 | $26.288 |
| Operating loss | $(13.534) | $(9.328) | $(39.213) | $(24.750) |
| Net loss | $(12.731) | $(12.458) | $(38.817) | $(34.591) |
| Operating cash used | — | $(37.025) | $(20.085) |
- Cost of goods sold was $2.148 million in Q3 and $5.188 million year to date, exceeding total revenue in both periods; this reflects, among other items, low-volume manufacturing costs and a $0.9 million DSUVIA inventory write-down in Q3. The filing does not provide a meaningful positive gross margin.
- At September 30, cash and cash equivalents were $21.949 million and short-term investments were $58.451 million, totaling $80.4 million, versus $105.7 million at December 31, 2018. Current assets were $85.7 million and current liabilities $11.4 million.
- Long-term debt was approximately $24.0 million, including $2.1 million current and $21.9 million noncurrent. The separate liability related to sold future royalties was $93.1 million, including $0.7 million current.
- Stockholders’ equity was a deficit of $28.3 million; accumulated deficit was $383.7 million. The company had 79.6 million common shares outstanding at September 30.
Material changes and notable items
- Revenue increased year over year, principally from higher Grünenthal collaboration revenue and initial DSUVIA sales, but product sales remained small.
- Year-to-date selling, general and administrative expense rose to $32.2 million from $13.1 million, primarily reflecting commercial-launch spending and increased personnel. Research and development expense fell to $3.6 million from $10.4 million as development work wound down and personnel shifted toward commercialization.
- Year-to-date operating cash use increased to $37.0 million from $20.1 million. The company also spent $3.2 million on property and equipment and reported $14.5 million of net financing cash flow, including the Oxford loan and equity-plan proceeds.
- In May 2019, AcelRx borrowed $25 million from Oxford, used about $8.9 million to repay Hercules obligations, and received $15.9 million net proceeds after costs and interest. The Oxford loan carries a variable rate (LIBOR subject to a 2.50% floor plus 6.75%), is interest-only until July 2020, and matures June 2023. It is secured by substantially all assets, requires at least $5 million of unrestricted cash, and contains restrictive covenants and default provisions.
- A revised estimate of expected payments under the royalty monetization caused noncash interest income rather than prior-period-style interest expense. Management said this estimate reduced net loss by $5.4 million year to date; it is an accounting estimate, not equivalent to cash generated from operations. A contingent gain was not recognized.
Outlook, risks and contingencies
- Management expected continuing operating losses and negative operating cash flows until DSUVIA achieves market acceptance and meaningful revenue. It forecast that existing capital resources would cover operations through the middle of Q4 2020, while a risk-factor passage says at least through the end of Q2 2020; these runway statements differ and warrant reconciliation.
- The company expected significant losses in 2020. It anticipated qualifying product on a new high-volume DSUVIA packaging line beginning in 2020 and expected the line to reduce cost of goods sold thereafter. The filing gives no specific revenue or earnings guidance.
- Key risks include limited DSUVIA adoption, payer coverage and hospital formulary access; opioid-related regulatory, safety, legal and reputational exposure; compliance with DSUVIA’s restricted-distribution REMS; reliance on contract manufacturers and a limited API supply source; and the unresolved timing and outcome of a Zalviso NDA resubmission.
- The Oxford loan’s cash covenant, secured claims, acceleration terms and cross-default provisions could constrain operations or liquidity. AcelRx also disclosed potential need for additional financing and dilution; up to $45.3 million remained available under its ATM equity sales agreement at quarter-end.
- The company reported no material legal proceedings and no defaults upon senior securities. Management concluded disclosure controls were effective and reported no material quarterly change in internal control over financial reporting.
Investor verification priorities
- Confirm that this AcelRx 10-Q, rather than a Talphera filing, is the intended document.
- Reconcile the Q2 versus mid-Q4 2020 cash-runway statements and review subsequent financing and cash-burn trends.
- Assess DSUVIA demand, hospital and payer access, pricing, and whether sales can grow enough to offset commercialization costs.
- Check the Zalviso NDA resubmission status and FDA concerns about device errors and inadvertent tablet dispensing.
- Review the Oxford loan covenants, minimum-cash requirement, interest and maturity obligations, and the large royalty-monetization liability.
- Evaluate the inventory write-down, negative manufacturing economics for Zalviso, and whether the planned packaging-line savings were achieved.